Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2019

Open Access 01-12-2019 | Tuberculosis | Research

Prognostic value of serum macrophage migration inhibitory factor levels in pulmonary tuberculosis

Authors: Qingjiang Wang, Wei Han, Junmei Niu, Bing Sun, Wei Dong, Guangpeng Li

Published in: Respiratory Research | Issue 1/2019

Login to get access

Abstract

Background

Macrophage migration inhibitory factor (MIF) makes chemokine-like functions and plays critical roles in various inflammatory diseases. This study was designed to explore the significance of MIF serum levels in predicting the prognosis of pulmonary tuberculosis (PTB) following anti-TB treatment.

Methods

Patients diagnosed with culture-confirmed PTB without treatment were included and the serum was collected. Levels of MIF in serum were quantified with immunoassay, and the levels of established biomarkers were also determined, including C-reactive protein (CRP) and Interleukin 6 (IL-6). The outcome was estimated with all-cause mortality, with the mortality in 12 months as the primary outcome and the mortality in 3, 6, 9 months as other outcomes. The prognostic value of MIF and other factors in PTB were tested.

Results

Two hundred eighty-seven PTB patients were included. The median MIF levels in patients with advanced disease, disseminated and drug-resistant TB were significantly higher than that observed in mild -to- moderate disease, non-disseminated and drug-sensitive TB. MIF levels in patients with the outcome of death were higher than those survived [28.0 ng/ml (Inter-quartile range [IQR]: 24.2–33.1) vs. 22.3 ng/ml (IQR: 18.7–26.5); P < 0.001]. Multivariate model analysis was performed for comparing the highest quartiles to the lowest quartile of MIF levels. MIF levels were related to the mortality, with an elevated mortality risk of 236% [Odds ratio (OR) = 3.36; 95% Confidence interval (CI): 1.21–15.14; P = 0.012]. The model was re-analysis after combing MIF with currently established risk indicators. The obtained Area Under the Receiver Operating Characteristic Curve (±standard error) was elevated from 0.81 (±0.035) to 0.84 (±0.031), with a significant difference before and after adding the MIF (difference, 0.03[0.004]; P = 0.03).

Conclusion

Serum level of MIF was a better biomarker than CRP or IL-6 for predicting death in HIV-negative PTB patients, and increased MIF serum levels were related to higher mortality.
Literature
1.
Shao Y, Yang D, Xu W, et al. Epidemiology of anti-tuberculosis drug resistance in a chinese population: current situation and challenges ahead [J]. BMC Public Health. 2011;11(1):110.PubMedPubMedCentral
2.
Li J, Li T, Du X, et al. The age-structured incidence and mortality of pulmonary tuberculosis reported in China, in 2005–15: a longitudinal analysis of national surveillance data [J]. Lancet. 2017;390:S12.
3.
Lin HH, Wang L, Zhang H, et al. Tuberculosis control in China: use of modelling to develop targets and policies [J]. Bull World Health Organ. 2015;93:790–8.PubMedPubMedCentral
4.
Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data [J]. Lancet. 2014;383(9934):2057–64.PubMed
5.
Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China [J]. N Engl J Med. 2012;366(23):2161–70.PubMed
6.
Gunluoglu G, Yazar EE, Veske NS, et al. Mean platelet volume as an inflammation marker in active pulmonary tuberculosis [J]. Multidiscip Respir Med. 2014;9(1):11.PubMedPubMedCentral
7.
Ünsal E, Aksaray S, Köksal D, et al. Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis [J]. Postgrad Med J. 2005;81(959):604–7.PubMedPubMedCentral
8.
Caner SS, Köksal D, Ozkara S, et al. The relation of serum interleukin-2 and C-reactive protein levels with clinical and radiological findings in patients with pulmonary tuberculosis [J]. Tuberkuloz ve toraks. 2007;55(3):238–45.PubMed
9.
Abakay O, Abakay A, Sen HS, et al. The relationship between inflammatory marker levels and pulmonary tuberculosis severity [J]. Inflammation. 2015;38(2):691–6.PubMed
10.
Ngobeni R, Abhyankar MM, Jiang NM, et al. Entamoeba histolytica–encoded homolog of macrophage migration inhibitory factor contributes to mucosal inflammation during amebic colitis [J]. J Infect Dis. 2017;215(8):1294–302.PubMedPubMedCentral
11.
Le Hiress M, Tu L, Ricard N, et al. Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor/CD74 complex [J]. Am J Respir Crit Care Med. 2015;192(8):983–97.PubMed
12.
Marinho CR, Nunez-Apaza LN, Martins-Santos R, Bastos KR, Bombeiro AL, Bucci DZ, et al. IFN gamma, but not nitric oxide or specific IgG, is essential for the in vivo control of low-virulence Sylvio X10/4 Trypanosoma cruzi parasites. Scand J Immunol. 2007;66:297–308.PubMed
13.
Roggero E, Piazzon I, Nepomnaschy I, Perez A, Velikovsky A, Revelli S, et al. Thymocyte depletion during acute Trypanosoma cruzi infection in C57BL/6 mice is partly reverted by lipopolysaccharide pretreatment. FEMS Immunol Med Microbiol. 2004;41:123–31.PubMed
14.
Shang Z, Wang J, Kuai S, et al. Serum macrophage migration inhibitory factor as a biomarker of active pulmonary tuberculosis [J]. Annals of laboratory medicine. 2018;38(1):9–16.PubMed
15.
Kuai SG, Ou QF, You DH, et al. Functional polymorphisms in the gene encoding macrophage migration inhibitory factor (MIF) are associated with active pulmonary tuberculosis [J]. Infectious Diseases. 2016;48(3):222–8.PubMed
16.
American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis. 1990;142:725–35.
17.
Huang CT, Lee LN, Ho CC, et al. High serum levels of procalcitonin and soluble TREM-1 correlated with poor prognosis in pulmonary tuberculosis [J]. J Infect. 2014;68(5):440–7.PubMed
18.
Crump JA, Reller LB. Two decades of disseminated tuberculosis at a university medical center: the expanding role of mycobacterial blood culture. Clin Infect Dis. 2003;37:1037–43.PubMed
19.
Falk AJ, O’Connor B, Pratt PC. Classification of pulmonary tuberculosis. 12th ed. New York: National Tuberculosis and Respiratory Disease Association; 1969.
20.
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.PubMed
21.
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72.PubMed
22.
Ellis SM. The spectrum of tuberculosis and non-tuberculous mycobacterial infection. Eur Radiol. 2004;14:E34–42.PubMed
23.
Sharma S, Bose M. Role of cytokines in immune response to pulmonary tuberculosis. Asian Pac J Allergy Immunol. 2001;19:213–9.PubMed
24.
Tong X, Yan Z, Zhou Q, et al. Association between the MIF-173G/C polymorphism and serum MIF levels with pulmonary tuberculosis: a meta-analysis [J]. Sci Rep. 2017;7(1):234.PubMedPubMedCentral
25.
Cooper AM, Khader SA. The role of cytokines in the initiation, expansion,and control of cellular immunity to tuberculosis. Immunol Rev. 2008;226:191–204.PubMedPubMedCentral
26.
Ameglio F, Casarini M, Capoluongo E, Mattia P, Puglisi G, Giosue S. Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. Int J Tuberc Lung Dis. 2005;9:98–104.PubMed
27.
Boom WH, Canaday DH, Fulton SA, Gehring AJ, Rojas RE, Torres M. Human immunity to M. Tuberculosis: T cell subsets and antigen processing. Tuberculosis. 2003;83:98–106.PubMed
28.
Denis M. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol. 1991;132:150–7.PubMed
29.
Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and mycobacterium tuberculosis survival in infected macrophages. Cell. 2004;119:753–66.PubMed
30.
Kim DK, Kim HJ, Kwon SY, et al. Nutritional deficit as a negative prognostic factor in patients with military tuberculosis. Eur Respir J. 2008;32:1031–6.PubMed
31.
Matos ED, Moreira Lemos AC. Association between serum albumin levels and in-hospital deaths due to tuberculosis. Int J Tuberc Lung Dis. 2006;10:1360–6.PubMed
32.
Ugajin M, Miwa S, Shirai M, et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis [J]. Eur Respir J. 2011;37(2):371–5.PubMed
33.
Yoon C, Chaisson LH, Patel SM, et al. Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis [J]. Int. J. Tuberc. Lung Dis. 2017;21(9):1013–9.PubMedPubMedCentral
34.
Chowdhury IH, Ahmed AM, Choudhuri S, et al. Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy [J]. Mol Immunol. 2014;62(1):159–68.PubMed
35.
Chandrashekara S, Anupama KR, Sambarey A, et al. High IL-6 and low IL-15 levels mark the presence of TB infection: a preliminary study [J]. Cytokine. 2016;81:57–62.PubMed
36.
Das R, Koo MS, Kim BH, et al. Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to mycobacterium tuberculosis [J]. Proc Natl Acad Sci. 2013;110(32):E2997–3006.PubMed
37.
Hashemi M, Sharifi-Mood B, Rasouli A, et al. Macrophage migration inhibitory factor-173 G/C polymorphism is associated with an increased risk of pulmonary tuberculosis in Zahedan, Southeast Iran [J]. EXCLI J. 2015;14:117.PubMedPubMedCentral
38.
Sadki K, Lamsyah H, Rueda B, et al. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population [J]. J. Genet. Genomics. 2010;37(4):257–64.PubMed
Metadata
Title
Prognostic value of serum macrophage migration inhibitory factor levels in pulmonary tuberculosis
Authors
Qingjiang Wang
Wei Han
Junmei Niu
Bing Sun
Wei Dong
Guangpeng Li
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2019
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-019-1004-3

Other articles of this Issue 1/2019

Respiratory Research 1/2019 Go to the issue

Research

Risk factors for diagnostic delay in idiopathic pulmonary fibrosis

Research

RNA-sequencing across three matched tissues reveals shared and tissue-specific gene expression and pathway signatures of COPD

Research

Second-hand smoke exposure in adulthood and lower respiratory health during 20 year follow up in the European Community Respiratory Health Survey

Review

Is cellular senescence involved in cystic fibrosis?

Research

Pulmonary arterial remodelling by deficiency of peroxisome proliferator-activated receptor-γ in murine vascular smooth muscle cells occurs independently of obesity-related pulmonary hypertension

Research

A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits